乙肝表面抗原阳性的弥漫大B细胞淋巴瘤研究进展  

Advances in research on diffuse large B-cell lymphoma positive for hepatitis B surface antigen

作　　者：卢冬雪 李晓霞[1] 侯金晓[1] 周晋[1] LU Dongxue;LI Xiaoxia;HOU Jinxiao

机构地区：[1]哈尔滨医科大学附属第一医院血液内科

出　　处：《临床血液学杂志》2019年第6期901-904,共4页Journal of Clinical Hematology

基　　金：黑龙江省社会科学基金(No:12541416)

摘　　要：弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)是非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL)中最常见的亚型,是一种呈高度异质性且病死率较高的恶性肿瘤。DLBCL发病机制尚不完全清楚,近年来有研究表明,DLBCL的发病与乙肝病毒(hepatitis B virus,HBV)感染具有一定的相关性。Diffuse large B-cell lymphoma(DLBCL)is the most common subtype of non-Hodgkin's lymphoma,which is a malignant tumor with high heterogeneity and high mortality.The pathogenesis of DLBCL is not completely clear.In recent years,some studies have shown that the incidence of DLBCL has a certain correlation with hepatitis B virus infection.This article reviews the research progress of epidemiology,molecular genetics,clinical features,treatment and prognosis of hepatitis B surface antigen-positive(HBsAg^+)DLBCL.

关 键 词：弥漫大B细胞淋巴瘤 乙肝 特征 治疗 预后 

分 类 号：R733.4[医药卫生—肿瘤]